{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T13:46:02Z","timestamp":1792590362847,"version":"4.5.0"},"reference-count":37,"publisher":"MyJove Corporation","issue":"229","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JoVE"],"DOI":"10.3791\/69741","type":"journal-article","created":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T00:02:25Z","timestamp":1772841745000},"source":"Crossref","is-referenced-by-count":0,"title":["Enhanced Remission and Survival Outcomes with Decitabine Plus Venetoclax in Additional Sex Comb Like 1 Mutated Acute Myeloid Leukemia"],"prefix":"10.3791","author":[{"given":"Mei","family":"Ding","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxue","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dai","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2098","published-online":{"date-parts":[[2026,3,6]]},"reference":[{"issue":"1","key":"ref1","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1182\/blood-2011-04-347872","type":"journal-article","article-title":"Acute leukemia incidence and patient survival among children and adults in the United States, 2001 - 2007","volume":"119","author":"Dores","year":"2012","unstructured":"Dores, G. M., Devesa, S. S., Curtis, R. E., Linet, M. S., Morton, L. M. Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007. Blood. 119 (1), 34-43 (2012).","journal-title":"Blood"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"5184","DOI":"10.1182\/blood-2023-186428","type":"journal-article","article-title":"State-level acute myeloid leukemia incidence and mortality trends and association with obesity in the United States","volume":"142","author":"Kang","year":"2023","unstructured":"Kang, L., Ma, X., Podoltsev, N. A., Stempel, J. M., Wang, R. State-level acute myeloid leukemia incidence and mortality trends and association with obesity in the United States. Blood. 142, 5184 (2023).","journal-title":"Blood"},{"issue":"6","key":"ref3","doi-asserted-by":"crossref","first-page":"6711","DOI":"10.1002\/cam4.5461","type":"journal-article","article-title":"Sex differences in adults with acute myeloid leukemia and the impact of sex on overall survival","volume":"12","author":"Stabellini","year":"2023","unstructured":"Stabellini, N. et al. Sex differences in adults with acute myeloid leukemia and the impact of sex on overall survival. Cancer Med. 12 (6), 6711-6721 (2023).","journal-title":"Cancer Med"},{"issue":"1","key":"ref4","doi-asserted-by":"crossref","first-page":"2557507","DOI":"10.1080\/07853890.2025.2557507","type":"journal-article","article-title":"Global, regional, and national epidemiology of acute myeloid leukemia (1990-2021): A statistical analysis of incidence, mortality, and dalys","volume":"57","author":"Wu","year":"2025","unstructured":"Wu, B. et al. Global, regional, and national epidemiology of acute myeloid leukemia (1990-2021): A statistical analysis of incidence, mortality, and dalys. Ann Med. 57 (1), 2557507 (2025).","journal-title":"Ann Med"},{"issue":"24","key":"ref5","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.2217\/fon-2022-0786","type":"journal-article","article-title":"Elderly patients with acute myeloid leukemia who only receive supportive care in the Surveillance, Epidemiology and End Results-Medicare database: Demographics, treatment patterns and outcomes","volume":"19","author":"Dharmani","year":"2023","unstructured":"Dharmani, C. et al. Elderly patients with acute myeloid leukemia who only receive supportive care in the Surveillance, Epidemiology and End Results-Medicare database: Demographics, treatment patterns and outcomes. Future Oncol. 19 (24), 1677-1693 (2023).","journal-title":"Future Oncol"},{"issue":"1","key":"ref6","doi-asserted-by":"crossref","first-page":"7","DOI":"10.14740\/jh1055","type":"journal-article","article-title":"Survival in elderly patients diagnosed with acute myeloid leukemia: A hospital-based study","volume":"12","author":"Mendoza-Urbano","year":"2022","unstructured":"Mendoza-Urbano, D. M. et al. Survival in elderly patients diagnosed with acute myeloid leukemia: A hospital-based study. J Hematol. 12 (1), 7 (2022).","journal-title":"J Hematol"},{"issue":"8","key":"ref7","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.3390\/cancers15082399","type":"journal-article","article-title":"Optimizing treatment options for newly diagnosed acute myeloid leukemia in older patients with comorbidities","volume":"15","author":"Oshikawa","year":"2023","unstructured":"Oshikawa, G., Sasaki, K. Optimizing treatment options for newly diagnosed acute myeloid leukemia in older patients with comorbidities. Cancers (Basel). 15 (8), 2399 (2023).","journal-title":"Cancers (Basel)"},{"issue":"8","key":"ref8","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1002\/cncr.33477","type":"journal-article","article-title":"Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach","volume":"127","author":"Kantarjian","year":"2021","unstructured":"Kantarjian, H. M., Kadia, T. M., Dinardo, C. D., Welch, M. A., Ravandi, F. Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach. Cancer. 127 (8), 1186-1207 (2021).","journal-title":"Cancer"},{"issue":"1","key":"ref9","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13045-021-01062-w","type":"journal-article","article-title":"Emerging agents and regimens for AML","volume":"14","author":"Liu","year":"2021","unstructured":"Liu, H. Emerging agents and regimens for AML. J Hematol Oncol. 14 (1), 49 (2021).","journal-title":"J Hematol Oncol"},{"issue":"8","key":"ref10","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s11864-020-00765-5","type":"journal-article","article-title":"Treatment of relapsed acute myeloid leukemia","volume":"21","author":"Thol","year":"2020","unstructured":"Thol, F. Ganser, A. Treatment of relapsed acute myeloid leukemia. Curr Treat Options Oncol. 21 (8), 66 (2020).","journal-title":"Curr Treat Options Oncol"},{"issue":"6","key":"ref11","doi-asserted-by":"crossref","first-page":"e530","DOI":"10.1016\/j.clml.2021.01.024","type":"journal-article","article-title":"Comparison of azacitidine and decitabine in myelodysplastic syndromes and acute myeloid leukemia: A network meta-analysis","volume":"21","author":"Liu","year":"2021","unstructured":"Liu, W., Zhou, Z., Chen, L., Wang, X. Comparison of azacitidine and decitabine in myelodysplastic syndromes and acute myeloid leukemia: A network meta-analysis. Clin Lymphoma Myeloma Leuk. 21 (6), e530-e544 (2021).","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"22","key":"ref12","doi-asserted-by":"crossref","first-page":"5677","DOI":"10.3390\/cancers13225677","type":"journal-article","article-title":"Use of azacitidine or decitabine for the up-front setting in acute myeloid leukaemia: A systematic review and meta-analysis","volume":"13","author":"Saiz-Rodriguez","year":"2021","unstructured":"Saiz-Rodriguez, M. et al. Use of azacitidine or decitabine for the up-front setting in acute myeloid leukaemia: A systematic review and meta-analysis. Cancers (Basel). 13 (22), 5677 (2021).","journal-title":"Cancers (Basel)"},{"issue":"2","key":"ref13","first-page":"60","type":"journal-article","article-title":"Asxl1 gene in aml","volume":"47","author":"Hurtado","year":"2021","unstructured":"Hurtado, R., Guirales, F., Tirado, C. A. Asxl1 gene in aml. J Assoc Genet Technol. 47 (2), 60-68 (2021).","journal-title":"J Assoc Genet Technol"},{"issue":"5","key":"ref14","first-page":"178","type":"journal-article","article-title":"Epigenetic modulation in oncology: In-silico mechanistic studies of emerging enhancer zeste of homolog 2 inhibitors","volume":"3","author":"Osman","year":"2025","unstructured":"Osman, O. B. et al. Epigenetic modulation in oncology: In-silico mechanistic studies of emerging enhancer zeste of homolog 2 inhibitors. Int J Clin Med Res. 3 (5), 178-192 (2025).","journal-title":"Int J Clin Med Res"},{"issue":"1","key":"ref15","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1186\/s12935-021-02233-y","type":"journal-article","article-title":"Risk factors affect accurate prognosis in asxl1-mutated acute myeloid leukemia","volume":"21","author":"Fan","year":"2021","unstructured":"Fan, Y. et al. Risk factors affect accurate prognosis in asxl1-mutated acute myeloid leukemia. Cancer Cell Int. 21 (1), 526 (2021).","journal-title":"Cancer Cell Int"},{"issue":"5","key":"ref16","doi-asserted-by":"crossref","first-page":"171","DOI":"10.61466\/ijcmr2050003","type":"journal-article","article-title":"Pyrrolizines: Natural and synthetic derivatives with diverse biological activities","volume":"2","author":"Aly","year":"2024","unstructured":"Aly, S. et al. Pyrrolizines: Natural and synthetic derivatives with diverse biological activities. Int J Clin Med Res. 2 (5), 171-184 (2024).","journal-title":"Int J Clin Med Res"},{"issue":"10","key":"ref17","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.3324\/haematol.2022.281214","type":"journal-article","article-title":"Molecular predictors of response to venetoclax plus hypomethylating agent in treatment-na\u00efve acute myeloid leukemia","volume":"107","author":"Gangat","year":"2022","unstructured":"Gangat, N. et al. Molecular predictors of response to venetoclax plus hypomethylating agent in treatment-na\u00efve acute myeloid leukemia. Haematologica. 107 (10), 2501 (2022).","journal-title":"Haematologica"},{"issue":"1","key":"ref18","doi-asserted-by":"crossref","first-page":"484","DOI":"10.3390\/ijms25010484","type":"journal-article","article-title":"Venetoclax and hypomethylating agent combination in myeloid malignancies: Mechanisms of synergy and challenges of resistance","volume":"25","author":"Mishra","year":"2023","unstructured":"Mishra, R., Zokaei Nikoo, M., Veeraballi, S., Singh, A. Venetoclax and hypomethylating agent combination in myeloid malignancies: Mechanisms of synergy and challenges of resistance. Int J Mol Sci. 25 (1), 484 (2023).","journal-title":"Int J Mol Sci"},{"issue":"3","key":"ref19","doi-asserted-by":"crossref","first-page":"78","DOI":"10.61466\/ijcmr2030003","type":"journal-article","article-title":"Relation between abo and RHD and prevalence and severity of COVID-19 disease","volume":"2","author":"Khalaf","year":"2024","unstructured":"Khalaf, A. M. et al. Relation between abo and RHD and prevalence and severity of COVID-19 disease. Int J Clin Med Res. 2 (3), 78-86 (2024).","journal-title":"Int J Clin Med Res"},{"issue":"9","key":"ref20","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1182\/bloodadvances.2022009010","type":"journal-article","article-title":"Comparison and validation of the 2022 european leukemianet guidelines in acute myeloid leukemia","volume":"7","author":"Lachowiez","year":"2023","unstructured":"Lachowiez, C. A. et al. Comparison and validation of the 2022 european leukemianet guidelines in acute myeloid leukemia. Blood Adv. 7 (9), 1899-1909 (2023).","journal-title":"Blood Adv"},{"issue":"1","key":"ref21","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/s41408-023-00835-5","type":"journal-article","article-title":"Comparison of the 2022 and 2017 European Leukemianet risk classifications in a real-life cohort of the pethema group","volume":"13","author":"Sargas","year":"2023","unstructured":"Sargas, C. et al. Comparison of the 2022 and 2017 European Leukemianet risk classifications in a real-life cohort of the pethema group. Blood Cancer J. 13 (1), 77 (2023).","journal-title":"Blood Cancer J"},{"issue":"4","key":"ref22","doi-asserted-by":"crossref","first-page":"101518","DOI":"10.1016\/j.beha.2023.101518","type":"journal-article","article-title":"Who, what, when, where, and why: New classification systems for acute myeloid leukemia and their impact on clinical practice","volume":"36","author":"Appelbaum","year":"2023","unstructured":"Appelbaum, F. R. Who, what, when, where, and why: New classification systems for acute myeloid leukemia and their impact on clinical practice. Best Pract Res Clin Haematol. 36 (4), 101518 (2023).","journal-title":"Best Pract Res Clin Haematol"},{"issue":"1","key":"ref23","doi-asserted-by":"crossref","first-page":"4622","DOI":"10.1038\/s41467-022-32103-8","type":"journal-article","article-title":"Unified classification and risk-stratification in acute myeloid leukemia","volume":"13","author":"Tazi","year":"2022","unstructured":"Tazi, Y. et al. Unified classification and risk-stratification in acute myeloid leukemia. Nat Commun. 13 (1), 4622 (2022).","journal-title":"Nat Commun"},{"issue":"2","key":"ref24","doi-asserted-by":"crossref","first-page":"342","DOI":"10.3324\/haematol.2022.280802","type":"journal-article","article-title":"Update on current treatments for adult acute myeloid leukemia: To treat acute myeloid leukemia intensively or non-intensively? That is the question","volume":"108","author":"Jaramillo","year":"2023","unstructured":"Jaramillo, S. Schlenk, R. F. Update on current treatments for adult acute myeloid leukemia: To treat acute myeloid leukemia intensively or non-intensively? That is the question. Haematologica. 108 (2), 342-352 (2023).","journal-title":"Haematologica"},{"issue":"4","key":"ref25","doi-asserted-by":"crossref","first-page":"101","DOI":"10.61466\/ijcmr3040003","type":"journal-article","article-title":"Treatment of non-small cell lung cancer with the nursing application of chemotherapy and traditional Chinese medicine: A meta-analysis","volume":"3","author":"Mohamed","year":"2025","unstructured":"Mohamed, B. M. Treatment of non-small cell lung cancer with the nursing application of chemotherapy and traditional Chinese medicine: A meta-analysis. Int J Clin Med Res. 3 (4), 101-112 (2025).","journal-title":"Int J Clin Med Res"},{"issue":"1","key":"ref26","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41408-024-01130-7","type":"journal-article","article-title":"Venetoclax with hypomethylating agents versus intensive chemotherapy in newly diagnosed acute myeloid leukemia with myelodysplasia related changes: A propensity score-matched analysis based on international consensus classification","volume":"14","author":"Wan","year":"2024","unstructured":"Wan, C.-L. et al. Venetoclax with hypomethylating agents versus intensive chemotherapy in newly diagnosed acute myeloid leukemia with myelodysplasia related changes: A propensity score-matched analysis based on international consensus classification. Blood Cancer J. 14 (1), 144 (2024).","journal-title":"Blood Cancer J"},{"key":"ref27","first-page":"100550","type":"journal-article","article-title":"Unveiling prognosis in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax through novel risk stratification","volume":"24","author":"Sun","year":"2025","unstructured":"Sun, J. Guo, Z. Unveiling prognosis in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax through novel risk stratification. Leuk Res Rep. 24 100550 (2025).","journal-title":"Leuk Res Rep"},{"issue":"12","key":"ref28","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/s41408-022-00770-x","type":"journal-article","article-title":"Venetoclax with decitabine versus decitabine monotherapy in elderly acute myeloid leukemia: A propensity score-matched analysis","volume":"12","author":"Kwag","year":"2022","unstructured":"Kwag, D. et al. Venetoclax with decitabine versus decitabine monotherapy in elderly acute myeloid leukemia: A propensity score-matched analysis. Blood Cancer J. 12 (12), 169 (2022).","journal-title":"Blood Cancer J"},{"issue":"10","key":"ref29","doi-asserted-by":"crossref","first-page":"E253","DOI":"10.1002\/ajh.25567","type":"journal-article","article-title":"Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed\/refractory acute myeloid leukemia","volume":"94","author":"Aldoss","year":"2019","unstructured":"Aldoss, I. et al. Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed\/refractory acute myeloid leukemia. Am J Hematol. 94 (10), E253 (2019).","journal-title":"Am J Hematol"},{"issue":"4","key":"ref30","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1038\/leu.2015.211","type":"journal-article","article-title":"Idh1 and idh2 mutations in myelodysplastic syndromes and role in disease progression","volume":"30","author":"Dinardo","year":"2016","unstructured":"Dinardo, C. D. et al. Idh1 and idh2 mutations in myelodysplastic syndromes and role in disease progression. Leukemia. 30 (4), 980-984 (2016).","journal-title":"Leukemia"},{"issue":"13","key":"ref31","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1182\/bloodadvances.2020001482","type":"journal-article","article-title":"Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure","volume":"4","author":"Ball","year":"2020","unstructured":"Ball, B. J. et al. Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure. Blood Adv. 4 (13), 2866-2870 (2020).","journal-title":"Blood Adv"},{"issue":"8","key":"ref32","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1002\/ajh.24072","type":"journal-article","article-title":"clinical outcome, and prognostic significance of IDH mutations in AML","volume":"90","author":"Dinardo","year":"2015","unstructured":"Dinardo, C. D. et al. Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML. Am J Hematol. 90 (8), 732-736 (2015).","journal-title":"Am J Hematol"},{"issue":"13","key":"ref33","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1158\/1078-0432.CCR-21-3467","type":"journal-article","article-title":"Impact of venetoclax and azacitidine in treatment-na\u00efve patients with acute myeloid leukemia and idh1\/2 mutations","volume":"28","author":"Pollyea","year":"2022","unstructured":"Pollyea, D. A. et al. Impact of venetoclax and azacitidine in treatment-na\u00efve patients with acute myeloid leukemia and idh1\/2 mutations. Clin Cancer Res. 28 (13), 2753-2761 (2022).","journal-title":"Clin Cancer Res"},{"issue":"5","key":"ref34","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/ejh.14278","type":"journal-article","article-title":"Real-world effectiveness of first-line azacitidine or decitabine with or without venetoclax in AML patients unfit for intensive therapy","volume":"113","author":"Acker","year":"2024","unstructured":"Acker, F. et al. Real-world effectiveness of first-line azacitidine or decitabine with or without venetoclax in AML patients unfit for intensive therapy. Eur J Haematol. 113 (5), 623-630 (2024).","journal-title":"Eur J Haematol"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1182\/blood-2021-153288","type":"journal-article","article-title":"Venetoclax plus decitabine for young adults with newly diagnosed ELN adverse-risk acute myeloid leukemia: Interim analysis of a prospective, multicenter, single-arm, phase 2 trial","volume":"138","author":"Chen","year":"2021","unstructured":"Chen, S. et al. Venetoclax plus decitabine for young adults with newly diagnosed ELN adverse-risk acute myeloid leukemia: Interim analysis of a prospective, multicenter, single-arm, phase 2 trial. Blood. 138, 35 (2021).","journal-title":"Blood"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood-2020-138773","type":"journal-article","article-title":"Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia","volume":"136","author":"Maiti","year":"2020","unstructured":"Maiti, A. et al. Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia. Blood. 136, 22-25 (2020).","journal-title":"Blood"},{"issue":"14","key":"ref37","doi-asserted-by":"crossref","first-page":"e71037","DOI":"10.1002\/cam4.71037","type":"journal-article","article-title":"Better response and prognosis of venetoclax plus hypomethylating agents over intensive chemotherapy in young adults with newly diagnosed ASXL1-mutated acute myeloid leukemia","volume":"14","author":"Cai","year":"2025","unstructured":"Cai, Y. et al. Better response and prognosis of venetoclax plus hypomethylating agents over intensive chemotherapy in young adults with newly diagnosed ASXL1-mutated acute myeloid leukemia. Cancer Med. 14 (14), e71037 (2025).","journal-title":"Cancer Med"}],"container-title":["Journal of Visualized Experiments"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/app.jove.com\/t\/69741\/enhanced-remission-survival-outcomes-with-decitabine-plus-venetoclax","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T13:18:52Z","timestamp":1792588732000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jove.com\/t\/69741\/enhanced-remission-survival-outcomes-with-decitabine-plus-venetoclax"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,6]]},"references-count":37,"journal-issue":{"issue":"229","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.3791\/69741","relation":{},"ISSN":["1940-087X"],"issn-type":[{"value":"1940-087X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,6]]}}}